Jenburkt Pharmaceuticals Limited (BOM:524731)

India flag India · Delayed Price · Currency is INR
998.30
-2.00 (-0.20%)
At close: Mar 9, 2026
1.78%
Market Cap 4.41B
Revenue (ttm) 1.65B
Net Income (ttm) 324.23M
Shares Out 4.41M
EPS (ttm) 73.47
PE Ratio 13.59
Forward PE n/a
Dividend 18.00 (1.80%)
Ex-Dividend Date Jul 11, 2025
Volume 1,091
Average Volume 977
Open 980.00
Previous Close 1,000.30
Day's Range 970.00 - 1,001.70
52-Week Range 944.00 - 1,410.00
Beta 0.31
RSI 37.77
Earnings Date May 19, 2026

About Jenburkt Pharmaceuticals

Jenburkt Pharmaceuticals Limited researches and develops, manufactures, and markets pharmaceutical and healthcare products in India. The company offers products in various therapeutic areas, such as pain management, analgesic and anti-pyretics, muscle relaxants, nutraceuticals, neuropathic pain, anti-arthritic, anti-infectives, antifungals, antiulcerants/antacids, aphrodisiacs, antimalarials, anthelmintics, cough and cold, and anti- diabetics, as well as consumer products. It offers its products under the Allerzine, CartiSafe Forte, Eberjen, EC... [Read more]

Industry Pharmaceutical Preparations
Founded 1985
Employees 779
Stock Exchange Bombay Stock Exchange
Ticker Symbol 524731
Full Company Profile

Financial Performance

In fiscal year 2025, Jenburkt Pharmaceuticals's revenue was 1.52 billion, an increase of 6.85% compared to the previous year's 1.42 billion. Earnings were 320.61 million, an increase of 23.42%.

Financial Statements

News

There is no news available yet.